Elisabetta Romagnoli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5410270/publications.pdf

Version: 2024-02-01

101 papers 3,353 citations

126858 33 h-index 54 g-index

101 all docs

101 docs citations

101 times ranked

3723 citing authors

#	Article	IF	CITATIONS
1	Impaired Immune Function in Patients With Chronic Postsurgical Hypoparathyroidism: Results of the EMPATHY Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2215-e2227.	1.8	16
2	HypoparaNet: A Database of Chronic Hypoparathyroidism Based on Expert Medical-Surgical Centers in Italy. Calcified Tissue International, 2018, 103, 151-163.	1.5	23
3	Long-term effect of testosterone replacement therapy on bone in hypogonadal men with Klinefelter Syndrome. Endocrine, 2018, 61, 327-335.	1.1	23
4	Parathyroid carcinoma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2018, 32, 877-889.	2.2	70
5	Skeletal Alterations and Parathyroid Function. , 2018, , 75-82.		O
6	Diagnostic accuracy of 3T magnetic resonance imaging in the preoperative localisation of parathyroid adenomas: comparison with ultrasound and 99mTc-sestamibi scans. European Radiology, 2018, 28, 4900-4908.	2.3	41
7	Vitamin D status in primary hyperparathyroidism: effect of genetic background. Endocrine, 2017, 55, 266-272.	1.1	24
8	Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy. Journal of Endocrinological Investigation, 2017, 40, 1321-1326.	1.8	36
9	Incidence and all-cause mortality for hip fracture in comparison to stroke, and myocardial infarction: a fifteen years population-based longitudinal study. Endocrine, 2017, 58, 320-331.	1.1	7
10	Assessment of trabecular bone score (TBS) in overweight/obese men: effect of metabolic and anthropometric factors. Endocrine, 2016, 54, 342-347.	1.1	45
11	Letter to the Editor: Comments on "Are biochemical markers of bone turnover representative of bone histomorphometry in 370 postmenopausal women?―by Chavassieux P, Portero-Muzy N, Roux JP, Garnero P, Chapurlat R Journal of Clinical Endocrinology and Metabolism, 2016, 101, L17-L18.	1.8	1
12	Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study. Acta Diabetologica, 2015, 52, 727-732.	1.2	69
13	Estimate of body composition by Hume's equation: validation with DXA. Endocrine, 2015, 49, 65-69.	1.1	6
14	Acute Management of Hypercalcemia. , 2015, , 617-629.		1
15	Six-year follow-up of a characteristic osteolytic lesion in a patient with tumor-induced osteomalacia. European Journal of Endocrinology, 2014, 170, K1-K4.	1.9	20
16	Osteoprotegerin Serum Levels in Primary Hyperparathyroidism and Changes Following Surgery. Hormone and Metabolic Research, 2014, 46, 375-375.	0.7	3
17	Assessment of fracture risk by the FRAX algorithm in men and women with and without type 2 diabetes mellitus: a crossâ€sectional study. Diabetes/Metabolism Research and Reviews, 2014, 30, 313-322.	1.7	32
18	Quality of life in patients with primary hyperparathyroidism. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 113-121.	0.7	9

#	Article	IF	CITATIONS
19	Bone damage in type 2 diabetes mellitus. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 1151-1157.	1.1	52
20	Hypovitaminosis D in primary hyperparathyroidism: to treat or not to treat? That is the question. Journal of Endocrinological Investigation, 2014, 37, 413-414.	1.8	8
21	Vitamin D supplementation: when and how?. Journal of Endocrinological Investigation, 2014, 37, 603-607.	1.8	20
22	Intermittent High Doses of Vitamin D: A Need for Further Studies?. Calcified Tissue International, 2013, 92, 487-488.	1.5	12
23	The effect of parathyroidectomy on chronic constipation in patients affected by primary hyperparathyroidism. Journal of Bone and Mineral Metabolism, 2013, 31, 690-694.	1.3	10
24	"Trabecular Bone Score―(TBS): An indirect measure of bone micro-architecture in postmenopausal patients with primary hyperparathyroidism. Bone, 2013, 53, 154-159.	1.4	135
25	Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group. Clinical Endocrinology, 2013, 79, 20-26.	1.2	32
26	Arrhythmias in primary hyperparathyroidism evaluated by exercise test. European Journal of Clinical Investigation, 2013, 43, 208-214.	1.7	21
27	Therapy of Osteoporosis. Medical Radiology, 2013, , 5-13.	0.0	0
28	Effects of Strontium Ranelate Administration on Calcium Metabolism in Female Patients with Postmenopausal Osteoporosis and Primary Hyperparathyroidism. Calcified Tissue International, 2013, 92, 15-22.	1.5	7
29	Several approaches for vitamin D determination by surface plasmon resonance and electrochemical affinity biosensors. Biosensors and Bioelectronics, 2013, 40, 350-355.	5.3	63
30	Parathyroidectomy eliminates arrhythmic risk in primary hyperparathyroidism, as evaluated by exercise test. European Journal of Endocrinology, 2013, 169, 255-261.	1.9	29
31	MANAGEMENT OF ENDOCRINE DISEASE: Value and limitations of assessing vitamin D nutritional status and advised levels of vitamin D supplementation. European Journal of Endocrinology, 2013, 169, R59-R69.	1.9	65
32	Long-Term Bioavailability After a Single Oral or Intramuscular Administration of 600,000 IU of Ergocalciferol or Cholecalciferol: Implications for Treatment and Prophylaxis. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2709-2715.	1.8	80
33	Effect of gender and geographic location on the expression of primary hyperparathyroidism. Journal of Endocrinological Investigation, 2013, 36, 123-6.	1.8	17
34	Effect of a single oral dose of 600,000 IU of cholecalciferol on muscle strength: a study in young women. Journal of Endocrinological Investigation, 2013, 36, 1051-4.	1.8	4
35	The combination of <scp>FRAX</scp> and <scp>A</scp> geing <scp>M</scp> ale <scp>S</scp> ymptoms scale better identifies treated <scp>HIV</scp> males at risk for major fracture. Clinical Endocrinology, 2012, 77, 672-678.	1.2	32
36	CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort. Cellular Oncology (Dordrecht), 2012, 35, 411-422.	2.1	67

#	Article	IF	CITATIONS
37	Vertebral morphometry by dual-energy X-ray absorptiometry (DXA) for osteoporotic vertebral fractures assessment (VFA). Radiologia Medica, 2012, 117, 1374-1385.	4.7	27
38	Diagnostic Performance of Vertebral Fracture Assessment by the Lunar iDXA Scanner Compared to Conventional Radiography. Calcified Tissue International, 2012, 91, 335-342.	1.5	40
39	Muscle strength and bone in healthy women: effect of age and gonadal status. Hormones, 2012, 11, 325-332.	0.9	19
40	Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone. Journal of Endocrinological Investigation, 2012, 35, 866-8.	1.8	20
41	Vertebral morphometry by X-ray absorptiometry: Which reference data for vertebral heights?. Bone, 2011, 49, 526-536.	1.4	15
42	Acute and chronic effects of hypercalcaemia on cortical excitability as studied by 5 Hz repetitive transcranial magnetic stimulation. Journal of Physiology, 2011, 589, 1619-1626.	1.3	15
43	Metabolic Changes Following 500Âμg Monthly Administration of Calcidiol: A Study in Normal Females. Calcified Tissue International, 2011, 89, 252-257.	1.5	21
44	Secondary Osteoporosis in Men and Women: Clinical Challenge of an Unresolved Issue. Journal of Rheumatology, 2011, 38, 1671-1679.	1.0	19
45	Effect of a Single Oral Dose of 600,000 IU of Cholecalciferol on Serum Calciotropic Hormones in Young Subjects with Vitamin D Deficiency: A Prospective Intervention Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4771-4777.	1.8	84
46	Regulation of PTH secretion by 25-hydroxyvitamin D and ionized calcium depends on vitamin D status: A study in a large cohort of healthy subjects. Bone, 2010, 47, 626-630.	1.4	30
47	Sex hormones and bone health in males. Archives of Biochemistry and Biophysics, 2010, 503, 110-117.	1.4	21
48	The Effect of Recombinant PTH($1\hat{a}\in 34$) and PTH($1\hat{a}\in 84$) on Serum Ionized Calcium, 1,25-Dihydroxyvitamin D, and Urinary Calcium Excretion: A Pilot Study. Calcified Tissue International, 2009, 85, 287-292.	1.5	9
49	Phalangeal Quantitative Ultrasound and Bone Mineral Density in Evaluating Cortical Bone Loss: A Study in Postmenopausal Women With Primary Hyperparathyroidism and Subclinical latrogenic Hyperthyroidism. Journal of Clinical Densitometry, 2009, 12, 456-460.	0.5	7
50	Measuring serum calcium before and after teriparatide treatment. Osteoporosis International, 2008, 19, 1807-1807.	1.3	2
51	The Effects of Alendronate Treatment in Osteoporotic Patients Affected by Monoclonal Gammopathy of Undetermined Significance. Calcified Tissue International, 2008, 82, 418-426.	1.5	45
52	Skeletal turnover, bone mineral density, and fractures in male chronic abusers of alcohol. Journal of Endocrinological Investigation, 2008, 31, 321-326.	1.8	67
53	Short and Long-Term Variations in Serum Calciotropic Hormones after a Single Very Large Dose of Ergocalciferol (Vitamin D2) or Cholecalciferol (Vitamin D3) in the Elderly. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3015-3020.	1.8	286
54	Monoclonal Gammopathy of Undetermined Significance. New England Journal of Medicine, 2007, 356, 2223-2224.	13.9	2

#	Article	lF	CITATIONS
55	Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance. British Journal of Haematology, 2006, 134, 485-490.	1.2	69
56	Osteoporosis intervention in ambulatory patients with previous hip fracture: a multicentric, nationwide Italian survey. Osteoporosis International, 2006, 17, 478-483.	1.3	41
57	The risk of fractures in postmenopausal women with primary hyperparathyroidism. European Journal of Endocrinology, 2006, 155, 415-420.	1.9	87
58	Vitamin D status as the major factor determining the circulating levels of parathyroid hormone: a study in normal subjects. Osteoporosis International, 2005, 16, 805-812.	1.3	74
59	Potential Clinical Utility of a New IRMA for Parathyroid Hormone in Postmenopausal Patients with Primary Hyperparathyroidism. Clinical Chemistry, 2004, 50, 626-631.	1.5	45
60	Vitamin D status in female patients with primary hyperparathyroidism: does it play a role in skeletal damage?. Clinical Endocrinology, 2004, 60, 81-86.	1.2	45
61	Quality of life in ambulatory postmenopausal women: the impact of reduced bone mineral density and subclinical vertebral fractures. Osteoporosis International, 2004, 15, 975-980.	1.3	77
62	Skeletal involvement in patients with diabetes mellitus. Diabetes/Metabolism Research and Reviews, 2004, 20, 196-204.	1.7	135
63	Bone metabolism in ochronotic patients. Journal of Internal Medicine, 2003, 254, 296-300.	2.7	37
64	Impact of fractures on health care in a major university hospital in Rome. Aging Clinical and Experimental Research, 2003, 15, 505-511.	1.4	6
65	Gender Differences in Serum Markers of Bone Resorption in Healthy Subjects and Patients with Disorders Affecting Bone. Osteoporosis International, 2002, 13, 171-175.	1.3	44
66	Uneven Deficits in Vertebral Bone Density in Postmenopausal Patients with Primary Hyperparathyroidism as Evaluated by Posterior–Anterior and Lateral Dual-Energy Absorptiometry. Osteoporosis International, 2002, 13, 618-623.	1.3	9
67	Short-term effects of surgery in post-menopausal patients with primary hyperparathyroidism and normal bone turnover. Journal of Endocrinological Investigation, 2001, 24, 575-579.	1.8	8
68	Biomarkers of Bone Turnover after a Short Period of Steroid Therapy in Elderly Men. Clinical Chemistry, 2001, 47, 1314-1316.	1.5	30
69	Massive Tumoral Calcinosis in a Patient on Long-Term Hemodialysis. Journal of Bone and Mineral Research, 2000, 15, 2056-2057.	3.1	4
70	Awareness, attitudes and opinions on osteoporosis of primary care physicians working in the metropolitan area of Rome: A brief report. Aging Clinical and Experimental Research, 2000, 12, 240-244.	1.4	7
71	Hypovitaminosis D in an Italian population of healthy subjects and hospitalized patients. British Journal of Nutrition, 1999, 81, 133-137.	1.2	124
72	Clinical Validation of a New Immunoradiometric Assay for Intact Human Osteocalcin. Calcified Tissue International, 1999, 64, 365-369.	1.5	16

#	Article	IF	CITATIONS
73	Assessment of Serum Total and Bone Alkaline Phosphatase Measurement in Clinical Practice. Clinical Chemistry and Laboratory Medicine, 1998, 36, 163-8.	1.4	23
74	Comment on Marked Improvement in Bone Mass after Parathyroidectomy in Osteitis Fibrosa Cysticag. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3758-3760.	1.8	1
75	Marked Improvement in Bone Mass After Parathyroidectomy in Osteitis Fibrosa CysticaAuthors' Response*h. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3760-3761.	1.8	1
76	The measurement of urinary amino-terminal telopeptides of type I collagen to monitor bone resorption in patients with primary hyperparathyroidism. Journal of Endocrinological Investigation, 1997, 20, 559-565.	1.8	11
77	Pulmonary lymphangioleiomyoma in a patient with multiple endocrine neoplasia Type I. Journal of Endocrinological Investigation, 1997, 20, 282-285.	1.8	7
78	Serum osteocalcin and bone mineral density at various skeletal sites: A study performed with three different assays. Translational Research, 1997, 129, 422-429.	2.4	35
79	Age-related changes in the global skeletal uptake of technetium-99m methylene diphosphonate in healthy women. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 1473-1477.	2.2	13
80	Reversal of Decreased Bone Mass by Antibiotic Treatment in a Patient With Whipple's Disease. American Journal of the Medical Sciences, 1996, 311, 145-147.	0.4	3
81	Quantitative ultrasound assessment of bone in patients with primary hyperparathyroidism. Calcified Tissue International, 1995, 56, 526-528.	1.5	30
82	Temporal relationship between bone loss and increased bone turnover: A longitudinal study following natural menopause. Journal of Endocrinological Investigation, 1995, 18, 723-728.	1.8	17
83	Letter to the editor: Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta. Journal of Bone and Mineral Research, 1995, 10, 335-336.	3.1	9
84	Serum carboxy-terminal propeptide of human type I procollagen in patients with primary hyperparathyroidism: studies in basal conditions and after parathyroid surgery. European Journal of Endocrinology, 1994, 130, 587-591.	1.9	38
85	Circulating levels of insulin-like growth factor binding protein 3 (IGFBP-3) and insulin-like growth factor I (IGF-I) in perimenopausal women. Osteoporosis International, 1994, 4, 305-308.	1.3	19
86	Reduced serum levels of carâ~y-terminal propeptide of human type I procollagen in a family with type I-A osteogenesis imperfecta. Metabolism: Clinical and Experimental, 1994, 43, 1261-1265.	1.5	21
87	Effect of estrogen deficiency on IGF-I plasma levels: Relationship with bone mineral density in perimenopausal women. Calcified Tissue International, 1993, 53, 1-6.	1.5	69
88	Serum osteocalcin in metabolic bone diseases: What is its real significance?. Journal of Endocrinological Investigation, 1993, 16, 277-279.	1.8	8
89	Trabecular bone mineral density in primary hyperparathyroidism: relationship to clinical presentation and biomarkers of skeletal turnover. Bone and Mineral, 1993, 20, 113-123.	2.0	54
90	Serum ionized calcium, parathyroid hormone and related variables: effect of age and sex. Bone and Mineral, 1993, 23, 183-193.	2.0	50

#	Article	IF	CITATIONS
91	Parathyroid storm: Immediate recognition and pathophysiological considerations. Bone, 1993, 14, 703-706.	1.4	6
92	Conventional and new diagnostic applications of a two-site immunochemiluminometric assay for parathyroid hormone S. Minisola. Journal of Endocrinological Investigation, 1992, 15, 483-489.	1.8	8
93	Effects of ipriflavone on bone remodeling in primary hyperparathyroidism. Bone and Mineral, 1992, 19, S27-S33.	2.0	18
94	Concurrent improvement of neuromuscular and skeletal involvement following surgery for primary hyperparathyroidism. Journal of Neurology, 1992, 239, 57-57.	1.8	11
95	Clinical usefulness of serum tartrate-resistant acid phosphatase activity determination to evaluate bone turnover. Scandinavian Journal of Clinical and Laboratory Investigation, 1991, 51, 517-524.	0.6	78
96	Platelet count, mean platelet volume and their relation to prognosis in cerebral infarction. Journal of Internal Medicine, 1990, 227, 11-14.	2.7	111
97	Coexistent multiple myeloma and MEN type 1 Postgraduate Medical Journal, 1990, 66, 879-880.	0.9	1
98	The effects of oophorectomy on skeletal metabolism. Journal of Steroid Biochemistry and Molecular Biology, 1990, 37, 457-459.	1.2	13
99	Studies on the clinical significance of serum α2HS-glycoprotein measurement in metabolic bone diseases. Clinica Chimica Acta, 1990, 189, 245-248.	0.5	2
100	Two-site assay of intact parathyroid hormone in primary hyperparathyroidism: studies in basal conditions, following adenoma removal and during calcium and EDTA infusion. Clinica Chimica Acta, 1990, 190, 239-248.	0.5	14
101	Clinical value of the measurement of bone remodelling markers in primary hyperparathyroidism. Journal of Endocrinological Investigation, 1989, 12, 537-542.	1.8	15